Feramda Biopharmaceutical

Company Overview

Snapshot

Founded in January 2017 by Prof. Benjamin Sredni and Joseph R. Ferencz, M.D., Feramda Biopharmaceutical operates with 1–10 employees. The company secured funding across one round from one investor. In December 2018, Feramda Biopharmaceutical received Seed funding from ATOORO Fund.

Business overview

Feramda Biopharmaceutical is a Health Tech & Life Sciences company focused on developing tellurium-based oral drugs. Its core technology aims to reduce the need for intravitreal anti-vascular endothelial growth factor injections in treating wet age-related macular degeneration, a condition that can lead to blindness. The company's molecules inhibit angiogenesis by increasing angiogenesis inhibitors and reducing inflammation in the eye, serving the pharmaceutical and life sciences markets.

Company Intelligence Q&A

What is Feramda Biopharmaceutical's primary focus?

Feramda Biopharmaceutical focuses on developing tellurium-based oral drugs for treating wet age-related macular degeneration, aiming to reduce the frequency of intravitreal anti-vascular endothelial growth factor injections.

When was Feramda Biopharmaceutical founded?

Feramda Biopharmaceutical was founded in January 2017.

Who are the founders of Feramda Biopharmaceutical?

The company was co-founded by Prof. Benjamin Sredni and Joseph R. Ferencz, M.D.

What is the status of Feramda Biopharmaceutical?

Feramda Biopharmaceutical is currently non-active and ceased to operate in June 2022.

Which investor participated in Feramda Biopharmaceutical's Seed funding round?

In December 2018, Feramda Biopharmaceutical received Seed funding from ATOORO Fund.